Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease of unknown etiology, which was characterized by irreversible lung function decrease and high mortality. Up till now, only two drugs, i.e. Pirfenidone and Nintedanib,have been approved by Food and Drug Administration (FDA) for therapy of IPF, and the treatment is less effective. Therefore, it is urgent to develop new therapeutic drugs. In recent years, studies had paid attention to lipid metabolism in IPF. In this review, we discussed recent major advances of lipid metabolism, biomarkers and clinical trials in IPF.
特发性肺纤维化（IPF）是一种病因不明的以肺间质纤维化和肺功能进行性下降为特征的间质性肺病。目前临床上经食品及药物管理局（FDA）批准的用于治疗IPF的药物只有吡非尼酮和尼达尼布，但治疗效果欠佳，IPF患者预后差，病死率高。因此开发新的治疗药物迫在眉睫。近年来，脂代谢研究在IPF中的作用引起越来越多的关注。本文就脂代谢在IPF的发病机制、生物学标志物及临床治疗研究进展进行综述。.